secwatch.observer — SEC 8-K summary
======================================

Issuer:     BICYCLE THERAPEUTICS PLC (BCYC)
CIK:        0001761612
Form:       8-K
Filed at:   2025-05-01T23:59:59+00:00
Accession:  0001104659-25-043014
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bicycle Therapeutics Q1 net loss $60.8M; cash $793M; Duravelo-3 trial recruiting
--------------------------------------------------------------------------------

- Net loss of $60.8M ($0.88 per share) vs $26.6M ($0.62) in Q1 2024; R&D expense $59.1M (+69% YoY).
- Cash and equivalents $793.0M as of March 31, 2025, down from $879.5M at Dec 31, 2024; runway into 2H 2027.
- Phase 1/2 Duravelo-3 trial for zelenectide pevedotin in NECTIN4-amplified breast cancer open and recruiting.
- Felix J. Baker to succeed Pierre Legault as Board chairman; Legault and Richard Kender retiring at June 17 AGM.
- 2 abstracts accepted for 2025 ASCO; dose selection for Duravelo-2 in mUC on track for 2H 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761612/000110465925043014/0001104659-25-043014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761612/000110465925043014/tm2513585d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-043014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer